Figure 3 from p97 Inhibition Synergistically Enhances Hypomethylating Therapy through Targeting of PLK1 in Acute Myeloid Leukemia
Steffan T. Nawrocki(University of Arizona), Kevin R. Kelly(Keck Hospital of USC), Kaijin Wu(University of Southern California), Claudia M. Espitia(The University of Texas System), P Zaránd, Julian Olea(University of Southern California), Claudia Villa Celi(University of Southern California), Alex Duong, David L. Drum, Natalie L. Hakim, Homa Dadrastoussi(University of Southern California), Madison E. Gamble(University of Arizona), Xuelian Chen(Jiangsu University), Jiang F. Zhong(University of Southern California), S. Sureshkumar(University of Arizona), Hittu Matta, Ning Wang, Jack Angeles, Harley Wu, Jennifer S. Carew(University of Arizona)
Cited by 0
Related Papers
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
|Cancer Letters|2008|426
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
|Clinical Cancer Research|2015|355